hVIVO plc (LON:HVO – Get Free Report) was up 9.9% on Monday . The stock traded as high as GBX 21.50 ($0.27) and last traded at GBX 21.24 ($0.26). Approximately 2,611,591 shares were traded during trading, a decline of 2% from the average daily volume of 2,672,759 shares. The stock had previously closed at GBX 19.33 ($0.24).
hVIVO Price Performance
The business has a 50-day moving average of GBX 20.14 and a two-hundred day moving average of GBX 25.64. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The firm has a market cap of £128.25 million, a P/E ratio of 628.33 and a beta of 0.97.
About hVIVO
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Read More
- Five stocks we like better than hVIVO
- Airline Stocks – Top Airline Stocks to Buy Now
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- What Are Earnings Reports?
- What Does the Future Hold for Eli Lilly?
- Why Invest in 5G? How to Invest in 5G Stocks
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
